Table 5 Correlation between clinicopathological variables and survival-univariate analysis

Age

<50

102

1

0.317

1

0.283

≥50

43

1.476 (0.688–3.166)

1.831 (0.606–5.533)

Performance

ECOG 0–1

139

1

0.686

1

0.888

ECOG 2

6

1.349 (0.316–5.756)

1.160 (0.148–9.073)

Initial clinical stage

IIA, IIB, IIIA

93

1

0.017

1

0.010

IIIB, IIIC

52

2.370 (1.116–4.815)

4.764 (1.462–15.525)

pCR

No

134

1

0.817

NA^#

NA^#

Yes

11

1.186 (0.281–5.005)

Pathologic stage

pCR~IIIA

113

1

0.288

1

0.086

IIIB, IIIC

32

1.525 (0.700–3.319)

2.608 (0.874–7.786)

Pathologic N stage

N0

42

1

0.636

1

0.566

N1–3

103

0.828 (0.378–1.812)

1.558 (0.342–7.099)

Radiologic response

Responder

100

1

0.515

1

0.683

Non-responder

45

0.776 (0.361–1.665)

1.258 (0.419–3.775)

Nuclear grade

I, II

41

1

0.151

1

0.141

III

87

1.894 (0.792–4.532)

2.689 (0.722–10.023)

Histologic grade

I, II

39

1

0.020

1

0.132

III

82

4.159 (1.248–13.865)

4.820 (0.621–32.387)

ER

Positive

64

1

0.001

1

0.028

Negative

81

5.410 (2.073–14.119)

9.921 (1.289–76.349)

PR

Positive

44

1

0.005

1

0.166

Negative

101

7.778 (1.851–32.673)

4.278 (0.547–33.476)

bcl-2

Positive

63

1

0.034

1

0.046

Negative

74

2.351 (1.068–5.175)

4.705 (1.030–21.490)

Ki-67

Low expression

56

1

0.038

1

0.082

High expression

85

2.357 (1.050–5.287)

3.263 (0.861–12.363)

p53

Low expression

67

1

0.869

1

0.670

High expression

76

1.063 (0.515–2.193)

1.281 (0.410–3.998)

c-erbB2

0/+/++

107

1

0.242

1

0.678

+++

38

1.555 (0.742–3.255)

1.273 (0.408–3.973)

Triple negative

No

98

1

0.002

1

0.029

Yes

47

3.148 (1.539–6.441)

3.430 (1.133–10.378)